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Public Health Service Guidelines
for the Management of Health-Care Worker
Exposures to HIV and Recommendations
for Postexposure Prophylaxis
Summary
This report updates and consolidates all previous PHS recommendations for
the management of health-care workers (HCWs) who have occupational expo-
sure to blood and other body fluids that may contain human immunodeficiency
virus (HIV); it includes recommendations for HIV postexposure prophylaxis
(PEP) and discusses the scientific rationale for PEP. The decision to recommend
HIV postexposure prophylaxis must take into account the nature of the exposure
(e.g., needlestick or potentially infectious fluid that comes in contact with a mu-
cous membrane) and the amount of blood or body fluid involved in the
exposure. Other considerations include pregnancy in the HCW and exposure to
virus known or suspected to be resistant to antiretroviral drugs. Assessments of
the risk for infection resulting from the exposure and of the infectivity of the
exposure source are key determinants of offering PEP. Systems should be in
place for the timely evaluation and management of exposed HCWs and for con-
sultation with experts in the treatment of HIV when using PEP.
Recommendations for PEP have been modified to include a basic 4-week
regimen of two drugs (zidovudine and lamivudine) for most HIV exposures and
an expanded regimen that includes the addition of a protease inhibitor (indinavir
or nelfinavir) for HIV exposures that pose an increased risk for transmission or
where resistance to one or more of the antiretroviral agents recommended for
PEP is known or suspected. An algorithm is provided to guide clinicians and
exposed health-care workers in deciding when to consider PEP.
Occupational exposures should be considered urgent medical concerns to
ensure timely administration of PEP. Health-care organizations should have pro-
tocols that promote prompt reporting and facilitate access to postexposure care.
Enrollment of HCWs in registries designed to assess side effects in HCWs who
take PEP is encouraged.
INTRODUCTION
Although preventing blood exposures is the primary means of preventing occupa-
tionally acquired human immunodeficiency virus (HIV) infection, appropriate
postexposure management is an important element of workplace safety. In January
1990, CDC issued a statement on the management of HIV exposures that included
considerations for zidovudine (ZDV) use for postexposure prophylaxis (PEP) (1 ). At
that time, data were insufficient to assess the efficacy of ZDV as a prophylactic agent
in humans or the toxicity of this drug in persons not infected with HIV. Although there
are still only limited data to assess safety and efficacy, additional information is now
available that is relevant to this issue.
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In December 1995, CDC published a brief report of a retrospective case-control
study of health-care workers (HCWs) from France, the United Kingdom, and the
United States exposed percutaneously to HIV; the study identified risk factors for HIV
transmission and documented that the use of ZDV was associated with a decrease in
the risk for HIV seroconversion (2 ). This information, along with data on ZDV efficacy
in preventing perinatal transmission (3 ) and evidence that PEP prevented or amelio-
rated retroviral infection in some studies in animals (4 ), prompted a Public Health
Service (PHS) interagency working group*, with expert consultation (5 ), in June 1996
to issue provisional recommendations for PEP for HCWs after occupational HIV expo-
sure (6 ).
Since the provisional recommendations were released, several new antiretroviral
drugs have been approved by the Food and Drug Administration (FDA), and more
information is available about the use and safety of antiretroviral agents in exposed
HCWs (7–10 ). In addition, questions have been raised about the use of chemoprophy-
laxis in situations not fully addressed in the 1996 recommendations, including when
not to offer PEP, what to do when the source of exposure or the HIV status of the
source person is unknown, how to approach PEP in HCWs who are or may be preg-
nant, and considerations for PEP regimens when the source person’s virus is known or
suspected to be resistant to one or more of the antiretroviral agents recommended for
PEP.
In May 1997, a meeting of expert consultants, convened by CDC to consider the
new information, prompted a PHS interagency working group† decision to issue up-
dated recommendations. This document addresses the management of occupational
exposure to HIV, including guidance in assessing and treating exposed HCWs, up-
dates previous recommendations for occupational postexposure chemoprophylaxis,
and updates and replaces all previous PHS guidelines and recommendations for occu-
pational HIV exposure management for HCWs. Included in this document is an
algorithm to guide decisions regarding the use of PEP for HIV exposures. The algo-
rithm and these recommendations together address most issues that may be
encountered during postexposure follow-up. As relevant information becomes avail-
able, updates of these recommendations will be published. Recommendations for
nonoccupational (e.g., sexual or pediatric) exposures are not addressed in these
guidelines.
DEFINITIONS OF HEALTH-CARE WORKERS AND EXPOSURE
In this report, “health-care worker” (HCW) is defined as any person (e.g., an em-
ployee, student, contractor, attending clinician, public-safety worker, or volunteer)
whose activities involve contact with patients or with blood or other body fluids from
patients in a health-care or laboratory setting. An “exposure” that may place an HCW
at risk for HIV infection and therefore requires consideration of PEP is defined as a
*This interagency working group comprised representatives of CDC, the Food and Drug Ad-
ministration, the Health Resources and Services Administration, and the National Institutes of
Health.
†This interagency working group comprised representatives of CDC, FDA, and the National
Institutes of Health. Information included in these recommendations may not represent FDA
approval or approved labeling for the particular product or indications in question. Specifically
the terms “safe” and “effective” may not be synonymous with the FDA-defined legal standards
for product approval.
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percutaneous injury (e.g., a needlestick or cut with a sharp object), contact of mucous
membrane or nonintact skin (e.g., when the exposed skin is chapped, abraded, or af-
flicted with dermatitis), or contact with intact skin when the duration of contact is
prolonged (i.e., several minutes or more) or involves an extensive area, with blood,
tissue, or other body fluids. Body fluids include a) semen, vaginal secretions, or other
body fluids contaminated with visible blood that have been implicated in the transmis-
sion of HIV infection (11,12 ); and b) cerebrospinal, synovial, pleural, peritoneal,
pericardial, and amniotic fluids, which have an undetermined risk for transmitting HIV
(11 ). In addition, any direct contact (i.e., without barrier protection) to concentrated
HIV in a research laboratory or production facility is considered an “exposure” that
requires clinical evaluation and consideration of the need for PEP.
Although one nonoccupational episode of HIV transmission has been attributed to
contact with blood-contaminated saliva (13 ), this incident involved intimate kissing
between sexual partners and is not similar to contact with saliva that may occur dur-
ing the provision of health-care services. Therefore, in the absence of visible blood in
the saliva, exposure to saliva from a person infected with HIV is not considered a risk
for HIV transmission; also, exposure to tears, sweat, or nonbloody urine or feces does
not require postexposure follow-up.*
Human breast milk has been implicated in perinatal transmission of HIV. However,
occupational exposure to human breast milk has not been implicated in HIV transmis-
sion to HCWs. Moreover, the contact HCWs may have with human breast milk is quite
different from perinatal exposure and does not require postexposure follow-up.
BACKGROUND
The rationale is provided here for the postexposure management and prophylaxis
recommendations given at the end of the document. Additional details concerning the
risk for occupational HIV transmission to HCWs and management of occupational HIV
exposures are available elsewhere (16–18 ).
Risk for Occupational Transmission of HIV to HCWs
Prospective studies of HCWs have estimated that the average risk for HIV transmis-
sion after a percutaneous exposure to HIV-infected blood is approximately 0.3% (95%
confidence interval [CI]=0.2%–0.5%) (16 ) and after a mucous membrane exposure is
0.09% (95% CI=0.006%–0.5%) (19 ). Although episodes of HIV transmission after skin
exposure have been documented (20 ), the average risk for transmission by this route
has not been precisely quantified because no HCWs enrolled in prospective studies
have seroconverted after an isolated skin exposure. The risk for transmission is esti-
mated to be less than the risk for mucous membrane exposures (21 ). The risk for
*Although exposure to these body substances generally is not considered a risk for occupational
HIV transmission, this does not negate the importance of handwashing and appropriate glove
use when contacting these body substances. Handwashing and appropriate glove use are part
of standard precautions for infection control to prevent transmission of nosocomial and
community-acquired pathogens and are required for compliance with the Occupational Safety
and Health Administration bloodborne pathogen standard (14,15 ). In addition, postexposure
evaluation for hepatitis B (and possibly hepatitis C) should be provided if contact with saliva
includes a possible portal of entry (i.e., nonintact skin, mucous membrane, or percutaneous
injury).
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transmission after exposure to fluids or tissues other than HIV-infected blood also has
not been quantified.
As of June 1997, CDC has received reports of 52 U.S. HCWs with documented HIV
seroconversion temporally associated with an occupational HIV exposure. An addi-
tional 114 episodes in HCWs are considered possible occupational HIV transmissions;
these workers reported that their infection was occupationally acquired and no other
risk for HIV infection was identified, but transmission of infection after a specific expo-
sure was not documented (22 ). Of the 52 documented episodes, 47 HCWs were
exposed to HIV-infected blood, one to a visibly bloody body fluid, one to an unspeci-
fied fluid, and three to concentrated virus in a laboratory. Forty-five exposures were
percutaneous, and five were mucocutaneous; one HCW had both a percutaneous and
a mucocutaneous exposure. The route of exposure for one person exposed to concen-
trated virus is uncertain. Of the percutaneous exposures, the objects involved
included a hollow-bore needle (41), a broken glass vial (two), a scalpel (one), and an
unknown sharp object (one) (CDC, unpublished data, 1998).
Epidemiologic and laboratory studies suggest that several factors may affect the
risk for HIV transmission after an occupational exposure. The one retrospective case-
control study of HCWs who had percutaneous exposure to HIV found that the risk for
HIV transmission was increased with exposure to a larger quantity of blood from the
source patient as indicated by a) a device visibly contaminated with the patient’s
blood, b) a procedure that involved a needle placed directly in a vein or artery, or c) a
deep injury (23 ). (A laboratory study that demonstrated that more blood is transferred
by deeper injuries and hollow-bore needles lends further support for the observed
variation in risk related to blood quantity [24 ]). The risk also was increased for expo-
sure to blood from source patients with terminal illness, possibly reflecting either the
higher titer of HIV in blood late in the course of AIDS or other factors (e.g., the pres-
ence of syncytia-inducing strains of HIV). It was estimated that the risk for HIV
transmission from exposures that involve a larger volume of blood, particularly when
the source patient’s viral load is probably high, exceeds the average risk of 0.3% (23 ).
The utility of viral load measurements from a source patient as a surrogate for es-
timating the viral titer for assessing transmission risk is not known. Plasma viral load
measurement (e.g., HIV RNA) reflects only the level of cell-free virus in the peripheral
blood. This measurement does not reflect the level of cell-associated virus in the pe-
ripheral blood or the level of virus in other body compartments (e.g., lymphatic
tissue). Although a lower viral load, or results that are below the limits of viral quanti-
fication, in the peripheral blood probably indicates a lower titer exposure, it does not
rule out the possibility of transmission; HIV transmission from persons with a plasma
viral load below the limits of viral quantification (based on the assay used at the time)
has been reported in instances of mother-to-infant transmission (25,26 ) and in one
HCW seroconversion (J.L. Gerberding, San Francisco General Hospital, unpublished
data, May 1997).
There is some evidence that host defenses also may influence the risk for HIV infec-
tion. In one small study, HIV-exposed but uninfected HCWs demonstrated an
HIV-specific cytotoxic T-lymphocyte (CTL) response when peripheral blood mono-
nuclear cells were stimulated in vitro with HIV mitogens (27 ). Similar CTL responses
have been observed in other populations with repeated HIV exposure without result-
ing infection (28–33 ). Among several possible explanations for this observation, one
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is that the host immune response sometimes may be able to prevent establishment of
HIV infection after a percutaneous exposure; another is that the CTL response simply
may be a marker for exposure.
HIV Seroconversion in HCWs
Data on the timing and clinical characteristics of seroconversion in HIV-exposed
HCWs are limited by the infrequency of infection following occupational exposure,
variations in postexposure testing intervals, and differences over time in the sensitiv-
ity of HIV-antibody testing methods. Among the HCWs with documented sero-
conversions reported to CDC for whom data are available, 81% experienced a syn-
drome compatible with primary HIV infection a median of 25 days after exposure
(CDC, unpublished data, 1998). In a recent analysis of 51 seroconversions in HCWs,
the estimated median interval from exposure to seroconversion was 46 days (mean:
65 days); an estimated 95% seroconverted within 6 months after the exposure (34 ).
These data suggest that the time course of HIV seroconversion in HCWs is similar to
that in other persons who have acquired HIV through nonoccupational modes of
transmission (35 ).
Three instances of delayed HIV seroconversion occurring in HCWs have been re-
ported; in these instances, the HCWs tested negative for HIV antibodies >6 months
postexposure but were seropositive within 12 months after the exposure (36,37; J.L.
Gerberding, San Francisco General Hospital, unpublished data, May 1997). DNA se-
quencing confirmed the source of infection in one instance. Two of the delayed
seroconversions were associated with simultaneous exposure to hepatitis C virus
(HCV) (37; J.L. Gerberding, San Francisco General Hospital, unpublished data, May
1997). In one case, co-infection was associated with a rapidly fatal HCV disease course
(37 ); however, it is not known whether HCV directly influences the risk for or course of
HIV infection or is a marker for other exposure-related factors.
Rationale for PEP
Considerations that influence the rationale and recommendations for PEP include
the pathogenesis of HIV infection, particularly the time course of early infection; the
biologic plausibility that infection can be prevented or ameliorated by using
antiretroviral drugs and direct or indirect evidence of the efficacy of specific agents
used for prophylaxis; and the risk/benefit of PEP to exposed HCWs. The following dis-
cussion considers each of these issues.
Role of Pathogenesis in Considering Antiretroviral Prophylaxis
Information about primary HIV infection indicates that systemic infection does not
occur immediately, leaving a brief “window of opportunity” during which post-
exposure antiretroviral intervention may modify viral replication. Data from studies in
animal models and in vitro tissue studies suggest that dendritic cells in the mucosa
and skin are the initial targets of HIV infection or capture and have an important role
in initiating HIV infection of CD4+ T-cells in regional lymph nodes (38 ). In a primate
model of simian immunodeficiency virus (SIV) infection, infection of dendritic-like
cells occurred at the site of inoculation during the first 24 hours following mucosal
exposure to cell-free virus. During the subsequent 24–48 hours, migration of these
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cells to regional lymph nodes occurred, and virus was detectable in the peripheral
blood within 5 days (39 ). HIV replication is rapid (generation time: 2.5 days) and re-
sults in bursts of up to 5,000 viral particles from each replicating cell (40; M.S. Saag,
University of Alabama, personal communication, September 1997). The exponential
increase in viral burden continues unless controlled by the immune system or other
mechanisms (e.g., exhaustion of available target CD4+ T-cells). Theoretically, initiation
of antiretroviral PEP soon after exposure may prevent or inhibit systemic infection by
limiting the proliferation of virus in the initial target cells or lymph nodes.
Efficacy of Antiretrovirals for PEP
Studies in animals and humans provide direct and indirect evidence of the efficacy
of antiretroviral drugs as agents for postexposure prophylaxis. In human studies and
in most animal studies, ZDV was the antiretroviral agent used for prophylaxis (26,41–
54 ). However, in more recent animal studies, newer agents also have been reported
to be effective (55,56 ).
Data from animal studies have been difficult to interpret, in part because of prob-
lems identifying a comparable animal model for humans. Most studies use a higher
inoculum for exposure than would be expected in needlestick injuries. Among the
animal studies, differences in controlled variables (e.g., choice of viral strain [based on
the animal model used], inoculum size, route of inoculation, time of prophylaxis initia-
tion, and drug regimen) make attempts to apply these results to humans difficult. In
the animal studies that showed efficacy of pre-exposure and/or postexposure prophy-
laxis, reported outcomes (4,57 ) have included a) suppression of viremia or delayed
antigenemia (41–47 ); b) drug-facilitated vaccine-type response (i.e., chemoprophy-
laxis sufficiently inhibited viral replication to permit formation of a long-lasting,
protective cellular immune response) (48–56 ); and c) definitive prevention of infection
(i.e., chemoprophylactic efficacy) (41,52–54 ). More recent refinements in methodol-
ogy have enabled studies more relevant to humans; in particular, the viral inocula
used in animal studies have been reduced to levels more analogous to human expo-
sures (54,56 ). The results of these studies provide additional evidence of
postexposure chemoprophylactic efficacy.
In studies of HIV-2 or SIV in nonhuman primates in which ZDV or 3’-fluorothymid-
ine was used, suppression or delay of antigenemia was the most common outcome;
prevention of infection was infrequent (43,52,58–60 ). However, two other antiretro-
viral agents, 2’,3’-dideoxy-3’-hydroxymethyl cytidine (BEA-005) and (R)-9-(2-phos-
phonylmethoxypropyl)adenine (PMPA), used to study PEP in primates have been
more effective in preventing infection. When PMPA was administered 48 hours before,
4 hours after, or 24 hours after intravenous SIV inoculation to long-tailed macaques, a
4-week regimen prevented infection in all treated animals (55 ). A 3-day regimen of
BEA-005 prevented SIV infection in 12 of 12 pigtailed macaques when administered
1–8 hours after intravenous inoculation; infection also was prevented in four of four
animals that received 3 days of BEA-005 within 10 minutes after HIV-2 inocula-
tion (56 ) .
Animal studies have demonstrated that early initiation of PEP and small inoculum
size are correlates of successful PEP. ZDV initiated 1 hour or 24 hours after intravenous
exposure to a rapidly lethal variant of SIV in pigtailed macaques prevented infection in
one of three animals and modified SIV disease in three of six animals, respectively;
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PEP initiated at 72 hours had no effect (54 ). In macaques administered ZDV or BEA-
005 1 to 72 hours after SIV intravenous challenge, earlier initiation of PEP was
correlated with delayed onset and peak of antigenemia, decreased duration of
antigenemia, and reduction in SIV serum titer; the most potent effect was evident
when PEP was initiated within 8 hours of exposure (43,56 ). Studies in primates and
murine and feline animal models have demonstrated that larger inocula decrease pro-
phylactic efficacy (47,48,53,60 ). In addition, delaying initiation, shortening the
duration, or decreasing the antiretroviral dose of PEP, individually or in combination,
decreased prophylactic efficacy (42,43,45,47,50,55 ).
There is little information with which to assess the efficacy of PEP in humans. Sero-
conversion is infrequent after an occupational exposure to HIV-infected blood;
therefore a prospective trial would need to enroll many thousands of exposed HCWs
to achieve the statistical power necessary to directly demonstrate PEP efficacy. During
1987–1989, the Burroughs-Wellcome Company sponsored a prospective placebo-
controlled clinical trial among HCWs to evaluate 6 weeks of ZDV prophylaxis; how-
ever, this trial was terminated prematurely because of low enrollment (61 ). Because
of current indirect evidence of PEP efficacy, it is unlikely that a placebo-controlled trial
in HCWs would ever be feasible.
In the retrospective case-control study of HCWs, after controlling for other risk fac-
tors for HIV transmission, the risk for HIV infection among HCWs who used ZDV as
PEP was reduced by approximately 81% (95% CI=43%–94%) (23 ). In addition, in a ran-
domized, controlled, prospective trial (AIDS Clinical Trial Group [ACTG] protocol 076)
in which ZDV was administered to HIV-infected pregnant women and their infants, the
administration of ZDV during pregnancy, labor, and delivery and to the infant reduced
transmission by 67% (3 ). Only 9%–17% (depending on the assay used) of the protec-
tive effect of ZDV was explained by reduction of the HIV titer in the maternal blood,
suggesting that ZDV prophylaxis in part involves a mechanism other than the reduc-
tion of maternal viral burden (26 ).
The limitations of all of these studies must be considered when reviewing evidence
of PEP efficacy. The extent to which data from animal studies can be extrapolated to
humans is largely unknown, and the exposure route for mother-to-infant HIV trans-
mission is not similar to occupational exposures; therefore these findings may not
reflect a similar mechanism of ZDV prophylaxis in HCWs. Although the results of the
retrospective case-control study of HCWs suggest PEP efficacy, the limitations of that
study include the small number of cases studied and the use of cases and controls
from different cohorts.
Failure of ZDV PEP to prevent HIV infection in HCWs has been reported in at least
14 instances (62–64; G. Ippolito, AIDS Reference Center, Rome, Italy, and J. Hepton-
stall, Communicable Disease Surveillance Center, London, United Kingdom, personal
communication, 1997). Although eight of the 13 source patients had taken ZDV, labo-
ratory assessment for ZDV resistance of the virus from the source patient was
performed in only three instances, two of which demonstrated reduced susceptibility
to ZDV. In addition to possible exposure to a ZDV-resistant strain of HIV, other factors
that may have contributed to the apparent failures in these instances may include a
high titer and/or large inoculum exposure, delayed initiation and/or short duration of
PEP, and possible factors related to the host (e.g., cellular immune system responsive-
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ness) and/or to the source patient’s virus (e.g., presence of syncytia-forming strains)
(62 ).
Antiretroviral Agents for PEP
Several antiretroviral agents from at least three classes of drugs are available for
the treatment of HIV disease. These include the nucleoside analogue reverse tran-
scriptase inhibitors (NRTIs), nonnuceloside reverse transcriptase inhibitors (NNRTIs),
and protease inhibitors (PIs) (See Appendix). Among these drugs, ZDV (an NRTI) is the
only agent shown to prevent HIV transmission in humans (2,3 ). Although there are
theoretical concerns that the increased prevalence of resistance to ZDV may diminish
its utility for PEP (65 ), no data are available to assess whether this is a factor for con-
sideration. Clinical data from the ACTG protocol 076 study documented that despite
genotypic evidence of maternal ZDV resistance, ZDV prevented perinatal transmission
(66 ). Thus, based on the available information, it is still reasonable that ZDV should
continue to be the first drug of choice for PEP regimens.
There are no data to directly support the addition of other antiretroviral drugs to
ZDV to enhance the effectiveness of the PEP regimen. However, in HIV-infected pa-
tients, combination regimens have proved superior to monotherapy regimens in
reducing HIV viral load (67,68 ). Thus, theoretically a combination of drugs with activ-
ity at different stages in the viral replication cycle (e.g., NRTIs with a PI) could offer an
additive preventive effect in PEP, particularly for occupational exposures that pose an
increased risk for transmission.
Determining which agents and how many agents to use or when to alter a PEP
regimen is largely empiric. Guidelines for the treatment of early HIV infection recom-
mend the use of three drugs (two NRTIs and a PI) (69 ); however, the applicability of
these recommendations to PEP remains unknown. In addition, the routine use of three
drugs for all occupational HIV exposures may not be needed. Although the use of a
highly potent regimen can be justified for exposures that pose an increased risk for
transmission, it is uncertain whether the potential additional toxicity of a third drug is
justified for lower-risk exposures. For this reason, the recommendations at the end of
this report provide guidance for two- and three-drug PEP regimens that are based on
the level of risk for HIV transmission represented by the exposure.
NRTIs that can be considered for use with ZDV for PEP are lamivudine (3TC), di-
danosine (ddI), and zalcitabine, each of which has been included in recommended
regimens that include ZDV (69 ). In previous CDC recommendations, 3TC was recom-
mended as a second agent for PEP based on greater antiretroviral activity of the
ZDV/3TC combination and its activity against many ZDV-resistant HIV strains without
substantially increased toxicity (6 ). Also, data suggest that ZDV-resistant mutations
develop more slowly in patients receiving the ZDV/3TC combination than those receiv-
ing ZDV alone (70 ), and in vitro studies indicate that the mutation associated with 3TC
resistance may be associated with reversal of ZDV phenotypic resistance (71 ). No
additional information has emerged to warrant altering the original recommendation
of 3TC as the second agent for PEP. In addition, because ZDV and 3TC are available in
a combination formulation (CombivirTM, manufactured by Glaxo Wellcome, Inc., Re-
search Triangle Park, NC), the use of 3TC may be more convenient for HCWs. However,
individual clinicians may prefer other NRTIs or combinations of other antiretroviral
agents based on local knowledge and experience in treating HIV infection and disease.
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The addition of a PI as a third drug for PEP following high-risk exposures is based
on the site of activity in the replication cycle (i.e., after viral integration has occurred)
and demonstrated effectiveness in reducing viral burden. Previously, indinavir (IDV)
was recommended as the PI for PEP because of its increased bioavailability when
compared with saquinavir and its more favorable immediate toxicity profile compared
with ritonavir (72 ). In addition, requirements for dose escalation when initiating rito-
navir make it less practical for use in PEP. Since the 1996 PEP recommendations were
published, nelfinavir (NEL) was approved for use by FDA and is now included in regi-
mens recommended for the treatment of primary HIV infection (69 ). Also, FDA
recently approved a soft-gel formulation of saquinavir (FortovaseTM, manufactured by
Hoffmann-LaRoche, Inc., Nutley, New Jersey) that has improved bioavailability rela-
tive to its hard-gel formulation (InviraseTM, manufactured by Hoffmann-LaRoche,
Inc.). However, the recommended dose of soft-gel saquinavir (1200 mg three times a
day) is twice that of the hard-gel formulation (600 mg three times a day) and necessi-
tates taking 18 pills a day, a factor that may influence HCW compliance if used for PEP.
Based on these considerations, either IDV or NEL is recommended as first choice for
inclusion in an expanded PEP regimen. If saquinavir is preferred by the prescribing
physician, the soft-gel formulation (FortovaseTM) should be used. Also, differences in
the side effects associated with IDV and NEL, discussed below, may influence which of
these agents is selected in a specific situation.
The NNRTIs (i.e., nevirapine and delavirdine) have not been included in these rec-
ommended regimens for PEP. As a class of antiretroviral agents, the NNRTIs are
fast-acting and very potent, making them appealing in concept for PEP. In addition,
there is some evidence of prophylactic efficacy (73 ). However, concerns about side
effects and the availability of alternative agents argue against routinely using this
class of drugs for initial PEP, although with expert consultation, an NNRTI might be
considered.
Side Effects and Toxicity of Antiretroviral Agents
An important goal of PEP is to encourage and facilitate compliance with a 4-week
PEP regimen. Therefore, the toxicity profile of antiretroviral agents, including the fre-
quency, severity, duration, and reversibility of side effects, is a relevant consideration.
All of the antiretroviral agents have been associated with side effects (See Appendix).
However, studies of adverse events have been reported primarily for persons with
advanced disease (and longer treatment courses) and therefore may not reflect the
experience of persons with less advanced disease or those who are uninfected (74 ).
Side effects associated with many of the NRTIs (e.g., ZDV or ddI) are chiefly gastro-
intestinal (e.g., nausea or diarrhea), and in general the incidence of adverse effects has
not been greater when these agents are used in combination (72 ).
All of the approved PIs may have potentially serious drug interactions when used
with certain other drugs, requiring careful evaluation of concomitant medications be-
ing used by an HCW before prescribing a PI and close monitoring for toxicity when an
HCW is receiving one of these drugs (See Appendix). PIs may inhibit the metabolism
of nonsedating antihistamines and other hepatically metabolized drugs; NEL and rito-
navir may accelerate the clearance of certain drugs, including oral contraceptives
(requiring alternative or additional contraceptive measures for women taking these
drugs). The use of PIs also has been associated with new onset of diabetes mellitus,
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hyperglycemia, diabetic ketoacidosis, and exacerbation of pre-existing diabetes melli-
tus (75–77 ). Nephrolithiasis has been associated with IDV use (including in HCWs
using the drug for PEP) (8 ); however, the incidence of this potential complication may
be limited by drinking at least 48 oz (1.5 L) of fluid per 24-hour period (e.g., six 8 oz
glasses of water throughout the day) (72 ). Rare cases of hemolytic anemia also have
been associated with the use of IDV. NEL, saquinavir, and ritonavir have been associ-
ated with the development of diarrhea; however, this side effect usually responds to
treatment with antimotility agents that can be prescribed for use, if necessary, at the
time any one of these drugs is prescribed for PEP. The manufacturer’s package insert
should always be consulted for questions about potential drug interactions.
Among HCWs receiving ZDV PEP, usually at doses of 1,000–1,200 mg per day (i.e.,
higher than the currently recommended dose), 50%–75% reported one or more sub-
jective complaints and approximately 30% discontinued the drug because of
symptoms (7,78,79 ). Common symptoms included nausea, vomiting, malaise or fa-
tigue, headache, or insomnia. Mild decreases in hemoglobin and absolute neutrophil
count also were observed. All side effects were reversed when PEP was discontinued.
Preliminary information about HCWs receiving combination drugs for PEP (usually
ZDV plus 3TC with or without a PI) suggests that approximately 50%–90% of HCWs
report subjective side effects that caused 24%–36% to discontinue PEP (8–10 ). One
study documented that combination regimens that included ZDV at a lower dose
(600 mg per day) were better tolerated than high-dose ZDV used alone (1,000–
1,200 mg per day) (10 ). However, serious side effects, including nephrolithiasis,
hepatitis, and pancytopenia, have been reported with the use of combination drugs
for PEP (9,80; J.L. Gerberding, San Francisco General Hospital, personal communica-
tion, May 1997).
Resistance to Antiretroviral Agents
Known or suspected resistance of the source virus to antiretroviral agents, particu-
larly to one or more agents that might be included in a PEP regimen, is a concern for
those making decisions about PEP. Resistance of HIV has been reported with all avail-
able antiretroviral agents (65 ). However, the relevance of exposure to a resistant virus
is not understood. Although transmission of resistant strains has been reported (81–
85 ), in the perinatal clinical trial that studied vertical HIV transmission (ACTG protocol
076), ZDV prevented perinatal transmission despite genotypic resistance of HIV to
ZDV in the mother (66 ). In addition, patients generally take more than one antiretro-
viral drug and, unless testing is performed, often it is difficult to know to which drug(s)
resistance exists. The complexity of this issue is further compounded by the fre-
quency of cross-resistance within drug classes.
Resistance should be suspected in source patients when there is clinical progres-
sion of disease or a persistently increasing viral load and/or a decline in CD4 T-cell
count despite therapy, or a lack of virologic response to a change in therapy. Neverthe-
less, in this situation it is unknown whether a modification in the PEP regimen is
necessary or will influence the outcome of an occupational exposure.
Antiretroviral Drugs in Pregnancy
Considerations for the use of antiretroviral drugs in pregnancy include their poten-
tial effect on the pregnant woman and on her fetus or neonate. The pharmacokinetics
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of antiretroviral drugs has not been completely studied in pregnant women. Some of
the antiretroviral drugs are known to cross the placenta, but data for humans are not
yet available for others (particularly the PIs). In addition, data are limited on the poten-
tial effects of antiretroviral drugs on the developing fetus or neonate (86 ). Decisions
on the use of specific drugs in pregnancy also are influenced by whether a drug has
specific adverse effects or might further exacerbate conditions associated with preg-
nancy, (e.g., drugs that cause nausea may be less tolerated when superimposed on
the nausea normally associated with pregnancy).
There are data on both ZDV and 3TC from clinical trials in HIV-infected pregnant
women. The most extensive experience has been with the use of ZDV after 14 weeks
of gestation in pregnant HIV-infected women in phase I studies and the perinatal
ACTG protocol 076 (4,87 ). The dose of ZDV for pregnant women is the same as that in
nonpregnant persons, and ZDV appears safe and well tolerated in both women and
their infants who have had a follow-up period of several years (88–90 ). Data from the
Antiretroviral Pregnancy Registry have not documented an increased risk for birth de-
fects in infants with in utero exposure to ZDV (91 ). There are limited data on use of
3TC alone or in combination with ZDV in late gestation in pregnant HIV-infected
women. As with ZDV, the pharmacokinetics and dose of 3TC appear to be similar to
those for nonpregnant persons. The drug appears safe during pregnancy for women
and infants, although long-term safety is not known (92,93 ).
Carcinogenicity and/or mutagenicity is evident in several in vitro screening tests for
ZDV and all other FDA-licensed nucleoside antiretroviral drugs. In some in vivo rodent
studies, high-dose lifetime continuous ZDV exposure (94 ) or very high dose in utero
ZDV exposure has been associated with the development of tumors in adult females
or their offspring (95,96 ). The relevance of these animal data to humans is unknown.
However, in 1997 an independent panel reviewed these data and concluded that the
known benefits of ZDV in preventing perinatal transmission, where the risk for trans-
mission without ZDV is 25%–30%, outweigh the hypothetical concerns about
transplacental carcinogenesis (97 ).
No data are available regarding pharmacokinetics, safety, or tolerability of any of
the PIs in pregnant women. The use of PIs in HIV-infected persons has been associated
with hyperglycemia; it is unknown whether the use of these agents during pregnancy
will exacerbate the risk for pregnancy-associated hyperglycemia. Therefore, close
monitoring of glucose levels and careful instruction regarding symptoms related to
hyperglycemia are recommended for pregnant HCWs receiving a PI for PEP. IDV is
associated with infrequent side effects in adults (i.e., hyperbilirubinemia and renal
stones) that could be problematic for the newborn. As the half-life of IDV in adults is
short, these concerns may be relevant only if the drug is administered shortly before
delivery.
RECOMMENDATIONS FOR THE MANAGEMENT OF
POTENTIALLY EXPOSED HCWs
Health-care organizations should make available to their workers a system that in-
cludes written protocols for prompt reporting, evaluation, counseling, treatment, and
follow-up of occupational exposures that may place HCWs at risk for acquiring any
bloodborne infection, including HIV. Employers also are required to establish
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exposure-control plans, including postexposure follow-up for their employees, and to
comply with incident reporting requirements mandated by the Occupational Safety
and Health Administration (15 ). Access to clinicians who can provide postexposure
care should be available during all working hours, including nights and weekends.
Antiretroviral agents for PEP should be available for timely administration (i.e., either
by providing access to PEP drugs on site or creating links with other facilities or
providers to make them available offsite). Persons responsible for providing post-
exposure counseling should be familiar with evaluation and treatment protocols and
the facility’s procedures for obtaining drugs for PEP.
HCWs should be educated to report occupational exposures immediately after they
occur, particularly because PEP is most likely to be effective if implemented as soon
after the exposure as possible (41,55,56 ). HCWs who are at risk for occupational expo-
sure to HIV should be taught the principles of postexposure management, including
options for PEP, as part of job orientation and ongoing job training.
Exposure Report
If an occupational exposure occurs, the circumstances and postexposure manage-
ment should be recorded in the HCW’s confidential medical record (usually on a form
the facility designates for this purpose). Relevant information includes
• date and time of exposure;
• details of the procedure being performed, including where and how the exposure
occurred, and if the exposure was related to a sharp device, the type of device
and how and when in the course of handling the device the exposure occurred;
• details of the exposure, including the type and amount of fluid or material and
the severity of the exposure (e.g., for a percutaneous exposure, depth of injury
and whether fluid was injected; or for a skin or mucous-membrane exposure, the
estimated volume of material and duration of contact and the condition of the
skin [e.g., chapped, abraded, or intact]);
• details about the exposure source (i.e., whether the source material contained
HIV or other bloodborne pathogen[s]), and if the source is an HIV-infected per-
son, the stage of disease, history of antiretroviral therapy, and viral load, if
known; and
• details about counseling, postexposure management, and follow-up.
Exposure Management
Treatment of an Exposure Site
Wounds and skin sites that have been in contact with blood or body fluids should
be washed with soap and water; mucous membranes should be flushed with water.
There is no evidence that the use of antiseptics for wound care or expressing fluid by
squeezing the wound further reduces the risk for HIV transmission. However, the use
of antiseptics is not contraindicated. The application of caustic agents (e.g., bleach) or
the injection of antiseptics or disinfectants into the wound is not recommended.
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Assessment of Infection Risk
After an occupational exposure, the source-person and the exposed HCW should
be evaluated to determine the need for HIV PEP. Follow-up for hepatitis B virus and
hepatitis C virus infections also should be conducted in accordance with previously
published CDC recommendations (98,99 ).
Evaluation of exposure. The exposure should be evaluated for potential to transmit
HIV based on the type of body substance involved and the route and severity of the
exposure. Exposures to blood, fluid containing visible blood, or other potentially in-
fectious fluid (including semen; vaginal secretions; and cerebrospinal, synovial,
pleural, peritoneal, pericardial, and amniotic fluids) or tissue through a percutaneous
injury (i.e., needlestick or other penetrating sharps-related event) or through contact
with a mucous membrane are situations that pose a risk for bloodborne transmission
and require further evaluation (Figure 1). In addition, any direct contact (i.e., personal
protective equipment either was not used or was ineffective in protecting skin or mu-
cous membranes) with concentrated HIV in a research laboratory or production
facility is considered an exposure that requires clinical evaluation to assess the need
for PEP.
For skin exposures, follow-up is indicated if it involves direct contact with a body
fluid listed above and there is evidence of compromised skin integrity (e.g., dermatitis,
abrasion, or open wound). However, if the contact is prolonged or involves a large
area of intact skin, postexposure follow-up may be considered on a case-by-case basis
or if requested by the HCW.
For human bites, the clinical evaluation must consider possible exposure of both
the bite recipient and the person who inflicted the bite. HIV transmission only rarely
has been reported by this route (100,101; CDC, unpublished data, 1998). If a bite re-
sults in blood exposure to either person involved, postexposure follow-up, including
consideration of PEP, should be provided.
Evaluation and testing of an exposure source. The person whose blood or body fluids
are the source of an occupational exposure should be evaluated for HIV infection. In-
formation available in the medical record at the time of exposure (e.g., laboratory test
results, admitting diagnosis, or past medical history) or from the source person may
suggest or rule out possible HIV infection. Examples of information to consider when
evaluating an exposure source for possible HIV infection include laboratory informa-
tion (e.g., prior HIV testing results or results of immunologic testing [e.g., CD4+
count]), clinical symptoms (e.g., acute syndrome suggestive of primary HIV infection
or undiagnosed immunodeficiency disease), and history of possible HIV exposures
(e.g., injecting-drug use, sexual contact with a known HIV-positive partner, un-
protected sexual contact with multiple partners [heterosexual and/or homosexual], or
receipt of blood or blood products before 1985).
If the source is known to have HIV infection, available information about this per-
son’s stage of infection (i.e., asymptomatic or AIDS), CD4+ T-cell count, results of viral
load testing, and current and previous antiretroviral therapy, should be gathered for
consideration in choosing an appropriate PEP regimen. If this information is not im-
mediately available, initiation of PEP, if indicated, should not be delayed; changes in
the PEP regimen can be made after PEP has been started, as appropriate.
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NoYes
What type of exposure has occurred?
Small Large
No PEP needed
STEP 1: Determine the Exposure Code (EC)
OPIM Blood or bloody fluid





Mucous membrane or 
skin, integrity 
compromised
Is the source material blood, bloody fluid, other potentially 
infectious material (OPIM),  or an instrument contaminated 





(e.g., several drops, major 
blood splash and/or 
longer duration [i.e., 
several minutes or more])
(e.g., solid needle, 
superficial scratch)
(e.g., large-bore hollow 
needle, deep puncture, 
visible blood on device, 
or needle used in source 
patient's artery or vein)
Exposures to OPIM must be evaluated on a case-by-case basis. In general, these body substances are 
considered a low risk for transmission in health-care settings. Any unprotected contact to concentrated HIV in 
a research laboratory or production facility is considered an occupational exposure that requires clinical 
evaluation to determine the need for PEP.
Skin integrity is considered compromised if there is evidence of chapped skin, dermatitis, abrasion, or open 
wound.
Contact with intact skin is not normally considered a risk for HIV transmission. However, if the exposure was 
to blood, and the circumstance suggests a higher volume exposure (e.g., an extensive area of skin was 
exposed or there was prolonged contact with blood), the risk for HIV transmission should be considered.
The combination of these severity factors (e.g., large-bore hollow needle and deep puncture) contribute to an 
elevated risk for transmission if the source person is HIV-positive.
Less Severe More Severe
EC 1 EC 2 EC 2 EC 3










This algorithm is inteded to guide initial decisions about PEP and should be used in conjunction with other 
guidance provided in this report.
*
FIGURE 1. Determining the need for HIV postexposure prophylaxis (PEP) after an
occupational exposure*
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What is the HIV status of the exposure source?
STEP 2: Determine the HIV Status Code (HIV SC)
STEP 3: Determine the PEP Recommendation
PEP may not be warranted. Exposure type does not pose a known risk for HIV 
transmission. Whether the risk for drug toxicity outweighs the benefit of PEP 
should be decided by the exposed HCW and treating clinician.
Consider basic regimen.     Exposure type poses a negligible risk for HIV 
transmission. A high HIV titer in the source may justify consideration of PEP. 
Whether the risk for drug toxicity outweighs the benefit of PEP should be 
decided by the exposed HCW and treating clinician.
Recommend basic regimen. Most HIV exposures are in this category; no 
increased risk for HIV transmission has been observed but use of PEP is 
appropriate.
Recommend expanded regimen.      Exposure type represents an increased HIV 
transmission risk.
Recommend expanded regimen. Exposure type represents an increased HIV 
transmission risk.
If the source or, in the case of an unknown source, the setting where the 
exposure occurred suggests a possible risk for HIV exposure and the EC 
is 2 or 3, consider PEP basic regimen.
Basic regimen is four weeks of zidovudine, 600 mg per day in two or three divided doses, and lamivudine, 
150 mg twice daily.
Expanded regimen is the basic regimen plus either indinavir, 800 mg every 8 hours, or nelfinavir, 750 mg 
three times a day.
Lower titer exposure
(e.g., asymptomatic and 
high CD4 count***)
Higher titer exposure
(e.g., advanced AIDS, primary HIV infection, high 













HIV SC PEP recommendation
HIV SC 1 HIV SC 2 HIV SC Unknown
No PEP needed
A source is considered negative for HIV infection if there is laboratory documentation of a negative HIV 
antibody, HIV polymerase chain reaction (PCR), or HIV p24 antigen test result from a specimen collected at or 
near the time of exposure and there is no clinical evidence of recent retroviral-like illness.
A source is considered infected with HIV (HIV positive) if there has been a positive laboratory result for HIV 
antibody, HIV PCR, or HIV p24 antigen or physician-diagnosed AIDS.
Examples are used as surrogates to estimate the HIV titer in an exposure source for purposes of 
considering PEP regimens and do not reflect all clinical situations that may be observed. Although a high 
HIV titer (HIV SC 2) in an exposure source has been associated with an increased risk for transmission, the 










FIGURE 1. Determining the need for HIV postexposure prophylaxis (PEP) after an
occupational exposure* — Continued
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If the HIV serostatus of the source person is unknown, the source person should be
informed of the incident and, if consent is obtained, tested for serologic evidence of
HIV infection. If consent cannot be obtained (e.g., patient is unconscious), procedures
should be followed for testing source persons according to applicable state and local
laws. Confidentiality of the source person should be maintained at all times.
HIV-antibody testing of an exposure source should be performed as soon as possi-
ble. Hospitals, clinics, and other sites that manage exposed HCWs should consult their
laboratories regarding the most appropriate test to use to expedite these results. An
FDA-approved rapid HIV-antibody test kit should be considered for use in this situ-
ation, particularly if testing by enzyme immunoassay (EIA) cannot be completed
within 24–48 hours. Repeatedly reactive results by EIA or rapid HIV-antibody tests are
considered highly suggestive of infection, whereas a negative result is an excellent
indicator of the absence of HIV antibody. Confirmation of a reactive result by Western
blot or immunofluorescent antibody is not necessary for making initial decisions
about postexposure management but should be done to complete the testing proc-
ess.
If the source is HIV seronegative and has no clinical evidence of acquired immu-
nodeficiency syndrome (AIDS) or symptoms of HIV infection, no further testing of the
source is indicated. It is unclear whether follow-up testing of a source who is HIV
negative at the time of exposure, but recently (i.e., within the last 3–6 months) en-
gaged in behaviors that pose a risk for HIV transmission, is useful in postexposure
management of HCWs; HCWs who become infected generally seroconvert before re-
peat testing of a source would normally be performed.
If the exposure source is unknown, information about where and under what cir-
cumstances the exposure occurred should be assessed epidemiologically for risk for
transmission of HIV. Certain situations, as well as the type of exposure, may suggest
an increased or decreased risk; an important consideration is the prevalence of HIV in
the population group (i.e., institution or community) from which the contaminated
source material is derived. For example, an exposure that occurs in a geographic area
where injecting-drug use is prevalent or on an AIDS unit in a health-care facility would
be considered epidemiologically to have a higher risk for transmission than one that
occurs in a nursing home for the elderly where no known HIV-infected residents are
present. In addition, exposure to a blood-filled hollow needle or visibly bloody device
suggests a higher-risk exposure than exposure to a needle that was most likely used
for giving an injection. Decisions regarding appropriate management should be indi-
vidualized based on the risk assessment.
HIV testing of needles or other sharp instruments associated with an exposure,
regardless of whether the source is known or unknown, is not recommended. The
reliability and interpretation of findings in such circumstances are unknown.
Clinical Evaluation and Baseline Testing of Exposed HCWs
Exposed HCWs should be evaluated for susceptibility to bloodborne pathogen in-
fections. Baseline testing (i.e., testing to establish serostatus at the time of exposure)
for HIV antibody should be performed. If the source person is seronegative for HIV,
baseline testing or further follow-up of the HCW normally is not necessary. If the
source person has recently engaged in behaviors that are associated with a risk for
HIV transmission, baseline and follow-up HIV-antibody testing (e.g., 3 and/or 6 months
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postexposure) of the HCW should be considered. Serologic testing should be made
available to all HCWs who are concerned that they may have been exposed to HIV.
For purposes of considering HIV PEP, the evaluation also should include informa-
tion about medications the HCW may be taking and any current or underlying medical
conditions or circumstances (i.e., pregnancy, breast feeding, or renal or hepatic dis-
ease) that may influence drug selection. Pregnancy testing should be offered to all
nonpregnant women of childbearing age whose pregnancy status is unknown.
HIV PEP
The following recommendations apply to situations where an HCW has had an ex-
posure to a source person with HIV or where information suggests that there is a
likelihood that the source person is HIV-infected. These recommendations are based
on the risk for HIV infection after different types of exposure and limited data regard-
ing efficacy and toxicity of PEP. Because most occupational HIV exposures do not
result in the transmission of HIV, potential toxicity must be carefully considered when
prescribing PEP. When possible, these recommendations should be implemented in
consultation with persons having expertise in antiretroviral therapy and HIV transmis-
sion.
Explaining PEP to HCWs
Recommendations for chemoprophylaxis should be explained to HCWs who have
sustained occupational HIV exposures (Figure 1). For exposures for which PEP is con-
sidered appropriate, HCWs should be informed that a) knowledge about the efficacy
and toxicity of drugs used for PEP are limited; b) only ZDV has been shown to prevent
HIV transmission in humans; c) there are no data to address whether adding other
antiretroviral drugs provides any additional benefit for PEP, but experts recommend
combination drug regimens because of increased potency and concerns about drug-
resistant virus; d) data regarding toxicity of antiretroviral drugs in persons without HIV
infection or in pregnant women are limited for ZDV and not known regarding other
antiretroviral drugs; and e) any or all drugs for PEP may be declined by the HCW.
HCWs who have HIV occupational exposures for which PEP is not recommended
should be informed that the potential side effects and toxicity of taking PEP outweigh
the negligible risk of transmission posed by the type of exposure.
Factors in Selection of a PEP Regimen
Selection of the PEP regimen should consider the comparative risk represented by
the exposure and information about the exposure source, including history of and
response to antiretroviral therapy based on clinical response, CD4+ T-lymphocyte
counts, viral load measurements, and current disease stage. Most HIV exposures will
warrant only a two-drug regimen, using two NRTIs, usually ZDV and 3TC. The addition
of a third drug, usually a PI (i.e., IDV or NEL), should be considered for exposures that
pose an increased risk for transmission or where resistance to the other drugs used
for PEP is known or suspected.
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Timing of PEP Initiation
PEP should be initiated as soon as possible. The interval within which PEP should
be started for optimal efficacy is not known. Animal studies have demonstrated the
importance of starting PEP within hours after an exposure (43,54,56 ). To assure timely
access to PEP, an occupational exposure should be regarded as an urgent medical
concern and PEP started as soon as possible after the exposure (i.e., within a few
hours rather than days). If there is a question about which antiretroviral drugs to use,
or whether to use two or three drugs, it is probably better to start ZDV and 3TC imme-
diately than to delay PEP administration. Although animal studies suggest that PEP
probably is not effective when started later than 24–36 hours postexposure (42,55,56) ,
the interval after which there is no benefit from PEP for humans is undefined. There-
fore, if appropriate for the exposure, PEP should be started even when the interval
since exposure exceeds 36 hours. Initiating therapy after a longer interval (e.g.,
1–2 weeks) may be considered for exposures that represent an increased risk for
transmission; even if infection is not prevented, early treatment of acute HIV infection
may be beneficial (69 ). The optimal duration of PEP is unknown. Because 4 weeks of
ZDV appeared protective in HCWs (2 ) , PEP probably should be administered for
4 weeks, if tolerated.
PEP if Serostatus of Source Person is Unknown
If the source person’s HIV serostatus is unknown at the time of exposure (including
when the source is HIV negative but may have had a recent HIV exposure), use of PEP
should be decided on a case-by-case basis, after considering the type of exposure and
the clinical and/or epidemiologic likelihood of HIV infection in the source (Figure 1). If
these considerations suggest a possibility for HIV transmission and HIV testing of the
source is pending, it is reasonable to initiate a two-drug PEP regimen until laboratory
results have been obtained and later modify or discontinue the regimen accordingly.
PEP if Exposure Source is Unknown
If the exposure source is unknown, use of PEP should be decided on a case-by-case
basis. Consideration should include the severity of the exposure and the
epidemiologic likelihood that the HCW was exposed to HIV.
PEP for Pregnant HCWs
If the HCW is pregnant, the evaluation of risk and need for PEP should be ap-
proached as with any other HCW who has had an HIV exposure. However, the decision
to use any antiretroviral drug during pregnancy should involve discussion between
the woman and her health-care provider regarding the potential benefits and potential
risks to her and her fetus.
Follow-up of HCWs Exposed to HIV
Postexposure Testing
HCWs with occupational exposure to HIV should receive follow-up counseling,
postexposure testing, and medical evaluation regardless of whether they receive PEP.
HIV-antibody testing should be performed for at least 6 months postexposure (e.g., at
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6 weeks, 12 weeks, and 6 months). It is unclear whether an extended follow-up period
(e.g., 12 months) is indicated in certain circumstances. Although rare instances of de-
layed HIV seroconversion have been reported (36,37, J.L. Gerberding, San Francisco
General Hospital, unpublished data, May 1997), the infrequency of this occurrence
does not warrant adding to HCWs’ anxiety by routinely extending the duration of
postexposure follow-up. Circumstances for which extending the duration of follow-up
have been suggested include the use of highly potent antiretroviral regimens (i.e.,
more than two drugs) because of theoretical concerns that HIV seroconversion could
be delayed, or simultaneous exposure to HCV. Data are insufficient for making a gen-
eral recommendation in these situations. However, this should not preclude a decision
to extend follow-up in an individual situation based on the clinical judgement of the
HCW’s health-care provider. HIV testing should be performed on any HCW who has an
illness that is compatible with an acute retroviral syndrome, regardless of the interval
since exposure. HIV-antibody testing using EIA should be used to monitor for sero-
conversion. The routine use of direct virus assays (e.g., HIV p24 antigen EIA or
polymerase chain reaction for HIV RNA) to detect infection in exposed HCWs gener-
ally is not recommended (34 ). Although direct virus assays may detect HIV infection
a few days earlier than EIA, the infrequency of HCW seroconversion and increased
costs of these tests do not warrant their routine use in this setting. Also, HIV RNA is
approved for use in established HIV infection; its reliability in detecting very early in-
fection has not been determined.
Monitoring and Management of PEP Toxicity
If PEP is used, drug-toxicity monitoring should be performed at baseline and again
2 weeks after starting PEP. Clinical judgement, based on medical conditions that may
exist in the HCW and any toxicity associated with drugs included in the PEP regimen,
should determine the scope of testing. Minimally these should include a complete
blood count and renal and hepatic chemical function tests. Monitoring for evidence of
hyperglycemia should be included for HCWs whose regimen includes any PI; if the
HCW is receiving IDV, monitoring for crystalluria, hematuria, hemolytic anemia, and
hepatitis also should be included. If toxicity is noted, modification of the regimen
should be considered after expert consultation; further diagnostic studies may be in-
dicated.
HCWs who fail to complete the recommended regimen often do so because of the
side effects they experience (e.g., nausea and diarrhea). These symptoms often can be
managed without changing the regimen by prescribing antimotility and antiemetic
agents or other medications that target the specific symptoms. In other situations,
modifying the dose interval (i.e., administering a lower dose of drug more frequently
throughout the day, as recommended by the manufacturer), may help promote adher-
ence to the regimen.
Counseling and Education
Although HIV infection following an occupational exposure occurs infrequently, the
emotional impact of the exposure often is substantial (102,103 ). In addition, HCWs are
given seemingly conflicting information. Although HCWs are told that there is a low
risk for HIV transmission, a 4-week regimen of PEP is recommended and they are
asked to commit to behavioral measures (i.e., sexual abstinence or condom use) to
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prevent secondary transmission, all of which influence their lives for several weeks to
months (102 ). Therefore, access to persons who are knowledgeable about occupa-
tional HIV transmission and who can deal with the many concerns an HIV exposure
may raise for the HCW is an important element of postexposure management.
HIV-exposed HCWs should be advised to use the following measures to prevent
secondary transmission during the follow-up period, especially during the first
6–12 weeks after the exposure when most HIV-infected persons are expected to sero-
convert: use sexual abstinence or condoms to prevent sexual transmission and to
avoid pregnancy; and refrain from donating blood, plasma, organs, tissue, or semen.
If the exposed HCW is breastfeeding, she should be counseled about the risk for HIV
transmission through breast milk, and discontinuation of breastfeeding should be
considered, especially following high-risk exposures. If the HCW chooses to receive
PEP, temporary discontinuation of breastfeeding while she is taking PEP should be
considered to avoid exposing the infant to these agents. NRTIs are known to pass into
breast milk; it is not known whether this also is true for PIs.
There is no need to modify an HCW’s patient-care responsibilities to prevent trans-
mission to patients based solely on an HIV exposure. If HIV seroconversion is
detected, the HCW should be evaluated according to published recommendations for
HIV-infected HCWs (104 ).
Exposed HCWs should be advised to seek medical evaluation for any acute illness
that occurs during the follow-up period. Such an illness, particularly if characterized
by fever, rash, myalgia, fatigue, malaise, or lymphadenopathy, may be indicative of
acute HIV infection but also may be due to a drug reaction or another medical condi-
tion.
Exposed HCWs who choose to take PEP should be advised of the importance of
completing the prescribed regimen. Information should be provided about potential
drug interactions and the drugs that should not be taken with PEP, the side effects of
the drugs that have been prescribed (See Appendix), measures to minimize these ef-
fects, and the methods of clinical monitoring for toxicity during the follow-up period.
They should be advised that the evaluation of certain symptoms should not be de-
layed (e.g., back or abdominal pain, pain on urination or blood in the urine, or
symptoms of hyperglycemia [i.e., increased thirst and/or frequent urination]).
RECOMMENDATIONS FOR THE SELECTION
OF DRUGS FOR PEP
The selection of a drug regimen for HIV PEP must strive to balance the risk for
infection against the potential toxicity of the agent(s) used. Because PEP is potentially
toxic, its use is not justified for exposures that pose a negligible risk for transmission
(Figure 1). Also, there is insufficient evidence to recommend a highly active regimen
for all HIV exposures. Therefore, two regimens for PEP are provided (Table 1): a “ba-
sic” two-drug regimen that should be appropriate for most HIV exposures and an
“expanded” three-drug regimen that should be used for exposures that pose an in-
creased risk for transmission (Figure 1) or where resistance to one or more
antiretroviral agents is known or suspected. When possible, the regimens should be
implemented in consultation with persons having expertise in antiretroviral treatment
and HIV transmission.
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Situations That Require Special Consideration
Resistance of the Source Virus to Antiretroviral Drugs
It is unknown whether drug resistance influences transmission risk; however, trans-
mission of drug-resistant HIV has been reported (81,82 ) and is therefore a theoretical
concern when choosing PEP regimens. If the source-person’s virus is known or sus-
pected to be resistant to one or more of the drugs included in the PEP regimen, the
selection of drugs to which the source person’s virus is unlikely to be resistant is rec-
ommended (69 ). If the resistance is to one class of antiretroviral drugs, the addition to
the basic PEP regimen of a drug from another class might be considered (e.g., addition
of a PI when a source patient has not been treated with a PI but has virus resistant to
one or more NRTIs). It is strongly recommended that PEP be started regardless of the
resistance status in the source virus; if resistance is known or suspected, a third or
fourth drug may be added to the regimen until consultation with a clinical expert in the
treatment of HIV infection or disease can be obtained.
Known or Suspected Pregnancy in the HCW
Pregnancy should not preclude the use of optimal PEP regimens, and PEP should
not be denied to an HCW solely on the basis of pregnancy. However, as discussed
previously, an occupationally exposed pregnant HCW must be provided with full infor-
mation about what is known and not known regarding the potential benefits and risks
associated with use of the antiretroviral drugs to her and her fetus for her to make an
informed decision regarding the use of PEP. The choice of antiretroviral drugs to use
for PEP in pregnant HCWs is complicated by the potential need to alter dosing because
of physiologic changes associated with pregnancy and the potential for short- or long-
term effects on the fetus and newborn. Thus, considerations that should be discussed
with a pregnant HCW include the potential risk for HIV transmission based on the type
of exposure; the stage of pregnancy (the first trimester being the period of maximal
organogenesis and risk for teratogenesis); and what is known about the pharmaco-
kinetics, safety, and tolerability of the drug or combination of drugs in pregnancy. 
TABLE 1. Basic and expanded postexposure prophylaxis regimens
Regimen
 category Application Drug regimen
Basic Occupational HIV exposures for
which there is a recognized
transmission risk (Figure 1).
4 weeks (28 days) of both zidovudine
600 mg every day in divided doses
(i.e., 300 mg twice a day, 200 mg
three times a day, or 100 mg every
4 hours) and lamivudine 150 mg
twice a day.
Expanded Occupational HIV exposures that
pose an increased risk for
transmission (e.g., larger volume of
blood and/or higher virus titer in
blood) (Figure 1).
Basic regimen plus either indinavir
800 mg every 8 hours or nelfinavir
750 mg three times a day.*
*Indinavir should be taken on an empty stomach (i.e., without food or with a light meal) and
with increased fluid consumption (i.e., drinking six 8 oz glasses of water throughout the day);
nelfinavir should be taken with meals.
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POSTEXPOSURE REGISTRIES
Health-care providers in the United States are encouraged to enroll HCWs who re-
ceive PEP in a confidential registry developed by CDC, Glaxo Wellcome Inc., and
Merck & Co., Inc., to assess toxicity; telephone (888) 737-4448 ([888] PEP-4HIV), or
write the HIV PEP Registry, 1410 Commonwealth Drive, Suite 215, Wilmington, NC
28405. Unusual or serious and unexpected toxicity from antiretroviral drugs should be
reported to the manufacturer and/or FDA, telephone (800) 332-1088.
Health-care providers also should report instances of prenatal exposure to
antiretroviral agents to the Antiretroviral Pregnancy Registry. The registry is an
epidemiologic project to collect observational, nonexperimental data on antiretroviral
drug exposure during pregnancy to assess potential teratogenicity. Referrals should
be directed to the Antiretroviral Pregnancy Registry, 1410 Commonwealth Drive, Suite
215, Wilmington, NC 28405; telephone (800) 258-4263 or (800) 722-9292, ext. 39437;
fax (800) 800-1052.
A protocol has been developed to evaluate HIV seroconversion in an HCW who
received PEP. These events can be reported to CDC, telephone (404) 639-6425.
RESOURCES FOR CONSULTATION
Clinicians who seek consultation on HIV PEP for assistance in managing an occupa-
tional exposure should access local experts in HIV treatment as much as possible. In
addition, the “National Clinicians’ Post-Exposure Prophylaxis Hotline (PEP-Line)” has
been created to assist clinicians with these issues; telephone (888) 448-4911. Other
resources and registries include the HIV Postexposure Prophylaxis Registry, the
Antiretroviral Pregnancy Registry, FDA, and CDC (Table 2).
TABLE 2. HIV postexposure prophylaxis resources and registries
Resource or registry Contact information
National Clinicians’ Postexposure Hotline Telephone: (888) 448-4911
HIV Postexposure Prophylaxis Registry Telephone: (888) 737-4448
      ([888] PEP4HIV)
Write:    1410 Commonwealth Drive
     Suite 215
     Wilmington, NC 28405
Antiretroviral Pregnancy Registry Telephone: (800) 258-4263
Fax:     (800) 800-1052
Write:    1410 Commonwealth Drive
     Suite 215
     Wilmington, NC 28405
Food and Drug Administration (for reporting
 unusual or severe toxicity to antiretroviral
 agents
Telephone: (800) 332-1088
CDC (for reporting HIV seroconversions in
 health-care workers who received PEP)
Telephone: (404) 639-6425
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ADMINISTRATIVE CONSIDERATIONS
Effective implementation of the elements of postexposure management detailed in
these recommendations may require various types of expertise. The assessment of
the severity of an exposure generally requires clinical training and experience (i.e.,
medical or nursing). However, the assessment of HIV infection risk and initiation of a
basic PEP regimen necessitates knowledge or experience in clinical epidemiology, in-
fection control, occupational health, or the clinical treatment of HIV. Decisions about
HIV PEP are particularly complex if PIs are used or there is concern about drug-
resistant virus. Thus, expert consultation when prescribing PEP is strongly encour-
aged. PEP protocols should list the names of readily available resources for
consultation and could include policies that require infectious disease evaluation be-
fore prescribing an expanded antiretroviral regimen. However, these efforts should
not delay initial implementation of PEP where it is appropriate.
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Appendix
FIRST-LINE DRUGS FOR HIV
POSTEXPOSURE PROPHYLAXIS (PEP)*





600 mg every day in divided doses (e.g., 300 mg twice a day, 200 mg three times a
day, or 100 mg every four hours).
Primary toxicities and/or side effects
Neutropenia, anemia, nausea, fatigue, malaise, headache, insomnia, and asthenia.
Comments






150 mg twice a day.
Primary toxicities and/or side effects
Headache, abdominal pain, diarrhea, and in rare cases, pancreatitis. Toxicity of ZDV
and 3TC when used in combination is approximately equal to that of ZDV alone.




1 tablet twice a day; each tablet contains 300 mg ZDV and 150 mg 3TC.
Primary toxicities and/or side effects
See above for ZDV and 3TC.
Comments
Caution should be used if co-administered with bone marrow suppressive drugs or
cytotoxic therapy.
*Information included in these recommendations may not represent Food and Drug Admini-
stration (FDA) approval or approved labeling for the particular products or indications in
question. Specifically, the terms “safe” and “effective” may not be synonymous with the
FDA-defined legal standards for product approval.






800 mg every 8 hours on an empty stomach (i.e., without food or with a light meal).
Primary toxicities and/or side effects
Nephrolithiasis, crystalluria, hematuria, nausea, headache, indirect hyperbiliru-
binemia, elevated liver function tests (LFTs), and hyperglycemia/diabetes.
Primary drug interactions†
No PI should be co-administered with terfenadine (Seldane®), astemizole (His-
manal®), cisapride (Propulsid®), triazolam, and midazolam. Rifampin should not be
administered with PIs. Cytochrome P450 metabolism inhibitors like ketoconazole
may increase PI plasma concentrations; dose reduction of the PI is only indicated
for indinavir. Ergot alkaloid preparations should not be used in combination with
PIs. If rifabutin is used concomitantly, rifabutin dose should be reduced because of
inhibition of rifabutin metabolism; with concomitant indinavir or nelfinavir use, re-
duce rifabutin dose by 50%.
Serum levels of PIs may be increased when multiple PIs are used in combination.
Comments
Incidence of nephrolithiasis may be reduced by consuming large quantities of





750 mg three times a day (with meals or a light snack).
Primary toxicities and/or side effects
Diarrhea and hyperglycemia/diabetes.
Primary drug interactions†
See above for indinavir.
Comments
Diarrhea usually can be controlled with over-the-counter antidiarrheal drugs (e.g.,
loperamide).
If oral contraceptives are being used, alternative or additional contraceptive meas-
ures should be used while taking nelfinavir.
*It is recommended that consultation with experts in the treatment of HIV infection and disease
be sought when considering the inclusion of PIs or the use of alternative agents in PEP
regimens.
†See package insert for other contraindications and possible drug interactions.
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0.75 mg every 8 hours.
Primary toxicities and/or side effects
Stomatitis and peripheral neuropathy.
Primary drug interactions*
Do not co-administer ddC with didanosine or stavudine because of the potential for
enhanced peripheral neuropathy.
Comments





200 mg twice a day; if body weight is <60 kg, 125 mg twice a day. Should be taken
on an empty stomach.
Primary toxicities and/or side effects
Pancreatitis, peripheral neuropathy, nausea, and diarrhea.
Primary drug interactions*
Do not co-administer ddI with ddC because of the potential for enhanced peripheral
neuropathy.
Comments
Peripheral neuropathy from ddI is usually after prolonged exposure.






40 mg twice a day; if body weight is <60 kg, 30 mg twice a day.
Primary toxicities and/or side effects
Peripheral neuropathy.
Primary drug interactions*
Do not co-administer d4T with ddC because of the potential for enhanced periph-
eral neuropathy.
Comments
Peripheral neuropathy from d4T is usually after prolonged exposure.
*See package insert for other contraindications and possible drug interactions.






600 mg twice a day; dose escalation recommended (300 mg twice a day for 1 day,
400 mg twice a day for 2 days, 500 mg twice a day for 1 day, then 600 mg twice a
day for duration of regimen).
Primary toxicities and/or side effects
Nausea, emesis, diarrhea, circumoral paresthesia, taste alteration, increased cho-
lesterol and triglycerides, hyperglycemia/diabetes, and increased LFTs.
Primary drug interactions†
No PI should be co-administered with terfenadine (Seldane®), astemizole (His-
manal®), cisapride (Propulsid®), triazolam, or midazolam. Rifampin should not be
administered with PIs. Cytochrome P450 metabolism inhibitors such as ketocona-
zole may increase protease inhibitor plasma concentrations. Ergot alkaloid
preparations should not be used in combination with PIs. Rifabutin should not be
co-administered with either saquinavir (because of reduction of saquinavir serum
concentrations) or ritonavir (because of increased rifabutin concentrations).
Serum levels of PIs may be increased when multiple PIs are used in combination.
Comments
Ritonavir should not be used with various antiarrhythmics and certain sedatives or
hypnotics. Ritonavir also has potential interactions with certain analgesics, anti-
biotics, antidepressants, anti-emetics, antifungals, calcium channel blockers, and
other medications.
If oral contraceptives are being used, alternative or additional contraceptive meas-
ures should be used while taking ritonavir.
Saquinavir (INVIRASE, hard-gel formulation) (FORTOVASE, soft-gel
formulation)
Dosage
INVIRASE, 600 mg three times a day with fatty meals; FORTOVASE, 1200 mg three
times a day within 2 hours of a meal. (If saquinavir is used for PEP, Fortovase should
be used.)
Primary toxicities and/or side effects
Diarrhea, headache, hyperglycemia/diabetes, and increased LFTs and triglycerides.
Primary drug interactions†
See above for ritonavir.
*It is recommended that consultation with experts in the treatment of HIV infection and disease
be sought when considering the inclusion of PIs or the use of alternative agents in PEP
regimens.
†See package insert for other contraindications and possible drug interactions.
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200 mg once a day for the first 2 weeks then 200 mg twice a day.
Primary toxicities and/or side effects
Rash (including rare cases of Stevens-Johnson syndrome), fever, nausea, head-
ache, and increased LFTs.
Primary drug interactions*
Nevirapine induces hepatic cytochrome CYP3A isoforms; however, drug interac-
tion studies with drugs metabolized by this enzyme have not been conducted.
Careful monitoring is therefore recommended if nevirapine is co-administered with
other drugs metabolized by this route because decreased serum concentrations
(and decreased effectiveness) of the other drugs may be observed (e.g., oral con-
traceptives, rifampin, and rifabutin). Use of nevirapine may decrease levels of
indinavir or saquinavir.
This drug should only be used in combination with other antiretroviral drugs.
Comments





400 mg three times a day
Primary toxicities and/or side effects
Rash (including rare cases of Stevens-Johnson syndrome), nausea, and increased
LFTs.
Primary drug interactions*
Delavirdine inhibits hepatic cytochrome CYP3A isoforms. Should not be co-
administered with terfenadine (Seldane®), astemizole (Hismanal®), cisapride
(Propulsid®), triazolam, midazolam, nifedipine, anticonvulsants, amphetamines, ri-
fabutin, or rifampin. Delavirdine may increase PI levels.
This drug should only be used in combination with other antiretroviral drugs.
Comments
Antacids and ddI decrease absorption of delavirdine and should be taken 2 hours
apart.
*See package insert for other contraindications and possible drug interactions.
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